Survival analysis in heart transplantation: results from an analysis of 1290 cases in a single center.
BACKGROUND
The clinical profiles of recipients and donors eligible for the procedure as well as the procedure itself have changed over time. We determined the impact of changes in baseline risk profiles at different transplant periods on outcome, and the time-specific distribution of causes of death.


METHODS
Adult heart transplantations were performed consecutively on 1290 patients. Three transplant periods were defined: 1989-1993, 1994-1998, and 1999-2004.


RESULTS
Recipient age and body mass index, previous cardiac surgery, high urgency status, need of ventricular assist device, waiting time (to transplantation and on ventricular assist device), donor age and body mass index, donor-recipient body mass index mismatch, and ischemic and cardiopulmonary bypass time were significantly different over the three transplant periods. There was, however, no significant difference in mortality risk. The major causes of deaths were: acute rejection, multiorgan failure, and right heart failure (<or=30 days); infection and acute rejection (31 days to 1 year); malignancy, acute rejection, and cardiac allograft vasculopathy (>1-5 years); cardiac allograft vasculopathy and malignancy (>5-10 years); and malignancy and infection (>10 years). The overall 1-, 5-, 10- and 15-year survival was respectively 77%, 67%, 53% and 42%. There was no difference in survival by different transplant periods (p=0.68).


CONCLUSIONS
Despite clearly increased baseline risk profiles over time, the outcome of adult heart transplantation remains stable and encouraging. Cardiac allograft vasculopathy, malignancy, and infection threaten the long-term survival.
Tjang
Yanto Sandy
YS
Department of Thoracic & Cardiovascular Surgery, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany. ystjang@hotmail.com
van der Heijden
Geert J M G
GJ
Tenderich
Gero
G
Grobbee
Diederick E
DE
Körfer
Reiner
R
D000328:Adult; D002423:Cause of Death; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D016027:Heart Transplantation / Q000379:methods / Q000401:mortality*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk; D016019:Survival Analysis; D013995:Time; D014019:Tissue Donors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents